ArticleJournal of neuro-oncology2014
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
Article in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.Nature medicine · 2019Trial
- Blocking TGF-β- and Epithelial-to-Mesenchymal Transition (EMT)-mediated activation of vessel-associated mural cells in glioblastoma impacts tumor angiogenesis.Free neuropathology · 2024Article
- Novel Treatment Strategies for Glioblastoma.Cancers · 2020Article
- Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.Journal of cancer research and clinical oncology · 2020Article
- Sevoflurane Regulates Glioma Progression by Circ_0002755/miR-628-5p/MAGT1 Axis.Cancer management and research · 2020Article
- Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.Journal of neuro-oncology · 2019Article
- Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series.CNS oncology · 2019Article
- Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.Advances in experimental medicine and biology · 2019Article
- Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice.Neuro-oncology practice · 2017Review
- The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
- Progression pattern and adverse events with bevacizumab in glioblastoma.Current oncology (Toronto, Ont.) · 2016Article
- The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.Journal of cancer research and clinical oncology · 2016Article
- Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.Journal of neuro-oncology · 2016Article
- Integrative radiogenomic analysis for genomic signatures in glioblastomas presenting leptomeningeal dissemination.Medicine · 2016Article
- Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma.Journal of neurology · 2015Article
- Bevacizumab for glioblastoma.Therapeutics and clinical risk management · 2015Review
- Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.Neuro-oncology · 2014Article
- Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?Neuro-oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma. It is not known if there are differences in outcome between early versus delayed BEV treatment of recurrent glioblastoma. We examined the relationship between the time of starting BEV treatment and outcomes in patients with recurrent glioblastoma. In this retrospective chart review, we identified patients with recurrent glioblastoma diagnosed between 2005 and 2011 who were treated with BEV alone or BEV-containing regimens. Data was analyzed to determine overall survival (OS) from time of diagnosis and progression free survival (PFS) from time of starting BEV. A total of 298 patients were identified, 112 patients received early BEV, 133 patients received delayed BEV, and 53 patients were excluded because they either progressed within 3 months of radiation or received BEV at the time of diagnosis. There was no significant difference in PFS between patients that received early BEV and those that received delayed BEV (5.2 vs. 4.3 months, p = 0.2). Patients treated with delayed BEV had longer OS when compared to those treated with early BEV (25.9 vs. 20.8 months, p = 0.005). In patients with recurrent glioblastoma, there was no significant difference in PFS from the time of starting BEV between early and delayed BEV. Although patients treated with delayed BEV seemed to have longer OS, a conclusion regarding OS outcome requires further prospective trials. These results may indicate that delaying treatment with BEV is not detrimental for survival of patients with recurrent glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.